The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Mount Sinai and Valley Health System to form partnership

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

MOUNT SINAI HEALTH SYSTEM and Valley Health System plan to form a partnership that will enable Valley to access Mount Sinai’s roster of clinical trials, as well as develop new programs and services.

In December 2015, Valley and Mount Sinai announced plans to collaborate on clinical programs, research and educational offerings. Mount Sinai and Valley plan to work together at Valley’s Blumenthal Cancer Center in Paramus and the main campus in Ridgewood by establishing a linked clinical information system.

According to Robert Korst, medical director of Valley’s Blumenthal Cancer Center, among the first Mount Sinai clinical trials that Valley patients will have access to include new treatments and treatment protocols for cutaneous malignancies, including melanoma and other skin cancers; genitourinary malignancies, including prostate and kidney cancers; and hematologic cancers and serious blood disorders, including leukemia, lymphoma, multiple myeloma and myelodysplastic syndromes. Some treatment protocols will include bone marrow transplantation and immunotherapeutic vaccines.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account